Health Archives - Page 7 of 8 - British Herald

Health

Health

The Lancet: Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease

The Ad5-nCoV vaccine, developed in China, is 57.5% effective against symptomatic COVID-19 infection and 91.7% effective against severe COVID-19 beginning 28 days post-vaccination, according to a phase 3 randomised control trial analysis. No vaccine-related serious adverse events were reported, and most adverse events, including injection-site pain, headache, drowsiness,
Health

The Lancet Respiratory Medicine: Children with poorly controlled asthma at higher risk of COVID-19 hospitalisation and should be prioritised for vaccination

Scottish study of over 750,000 school-aged children finds 5–17 year olds with poorly controlled asthma (who have been hospitalised with asthma or prescribed two or more courses of oral steroids for asthma within the past two years) are between three to six times more likely to be hospitalised with COVID-19 compared to those without asthma. […]
Health

THE LANCET: COVID-19 pandemic led to stark rise in depressive and anxiety disorders globally in 2020, with women and younger people most affected

First global estimates of impact of the COVID-19 pandemic on mental health in 2020 suggests additional 53 million cases of major depressive disorder and 76 million cases of anxiety disorders were due to the pandemic. Women and younger people were the most affected by major depressive disorder and anxiety disorders in 2020. Countries hit hardest […]
Health

THE LANCET: Two doses of Pfizer-BioNTech vaccine are highly effective against COVID-19 hospitalizations for at least six months

The Lancet: Two doses of Pfizer-BioNTech vaccine are highly effective against COVID-19 hospitalizations for at least six months Pfizer-BioNTech (BNT162b2) vaccine effectiveness against hospitalization for all variants, including delta, remains high (90%) for at least six months. Vaccine effectiveness against all infections of BNT162b2 waned during the six-month study